Treatment with anti-SARS-CoV-2 monoclonal antibodies in pregnant and postpartum women: first experiences in Florence, Italy.
Tommaso ManciulliGiulia ModiIrene CampolmiBeatrice BorchiMichele TrottaMichele SpinicciFilippo LagiAlessandro BartoloniLorenzo ZammarchiPublished in: Infection (2022)
Although preliminary data should be interpreted with caution, it is remarkable how mAbs were well tolerated by pregnant women with COVID-19. Further data on mAbs in this special population should be collected but the use of mAbs in pregnant and postpartum patients should be considered. Even thus oral antivirals are becoming available, they are not recommended in pregnant and postpartum women. This population may specifically benefit from treatment with last generation mAbs.
Keyphrases
- replacement therapy
- sars cov
- pregnant women
- end stage renal disease
- polycystic ovary syndrome
- ejection fraction
- electronic health record
- newly diagnosed
- chronic kidney disease
- mental health
- pregnancy outcomes
- machine learning
- peritoneal dialysis
- deep learning
- data analysis
- combination therapy
- skeletal muscle
- artificial intelligence